OTLK – outlook therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
Form SC 13G/A Outlook Therapeutics, Filed by: GREAT POINT PARTNERS LLC
Form SC 13G/A Outlook Therapeutics, Filed by: Velan Capital Investment Management LP
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Gangolli Julian S
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Auffarth Gerd
Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Haddadin Yezan Munther
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.